YolTech Secures Patent for Innovative DNA Editing System

Shanghai, China, April 26, 2024 – YolTech Therapeutics, a biotech company pioneering in vivo gene editing therapies,  announces acquisition of a patent for DNA editing system granted by the National Intellectual Property Administration (CNIPA),reaffirming strength in precision genetic engineering.

The newly patented DNA editing system comprises five CRISPR-Cas editors from the Cas12 family. Its innovative design enables targeted modifications at the molecular level with unparalleled accuracy and efficiency. This technology holds immense promise for a wide range of applications, including gene therapy and biomedical research.

"We are thrilled to announce the acquisition of this patent, which further solidifies our strength in genetic innovation," remarked Dr.Yuxuan Wu, founder and CEO. "This achievement reflects our commitment to pushing the boundaries of in vivo gene editing development and our dedication to benefiting patients. "

In addition, this patent serves as the basis for an international Patent Cooperation Treaty (PCT) application, as the company aims to bring feasible therapies to patients all over the world and contribute to human health.

About YolTech

YolTech Therapeutics is a pioneering gene editing company dedicated to develop a robust gene editing medicines to treat patients with serious diseases, which has built leading high-throughput evolution platform and innovative LNP deliver system. It possesses strong capability of novel Cas and base editor discovery and exceptional in-house LNP production capacity for GMP manufactory, with independent intellectual property rights and core patent protection globally. It has created a pipeline with 10+ genetic medicines focusing on cardiovascular diseases, metabolic diseases, infectious diseases as well as more common and rare diseases. Clinical trial clearance has been received for its leading in vivo gene editing asset YOLT-201 in March 2024.